Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leading Korean Pharma Companies Issued Fines In First Court Intervention Case Over Rebates

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In the first court-involved case over rebates, three leading local South Korean pharma companies were issued stiff fines for "excessively unfair" business practices incurred by providing rebates to doctors and hospital

You may also be interested in...



Korea's Finance Ministry Seeks Wider Public Access To OTC Products; Sparks Protests From Pharmacists

SEOUL -The Ministry of Strategy and Finance is moving to allow sales of over-the-counter drugs at convenience stores as part of a continuing effort to make the local pharmaceutical sector internationally more competitive by removing longstanding, albeit irregular, business practices. As it stands now in Korea, OTC products must be purchased from pharmacists

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

Related Content

UsernamePublicRestriction

Register

SC072358

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel